For decades, the pharmaceutical landscape was clearly demarcated: on one side, the innovators—brand-name manufacturers pouring billions into research and development, […]

The New Pharmaceutical Battleground: Why Method-of-Use Patents Define the Front Line Intellectual property is not merely a legal asset; it

I. Executive Summary This report provides a comprehensive analysis of the role of generic drug manufacturers in the complex ecosystem

Introduction: The High-Stakes Gamble of Drug Spend Forecasting Forecasting future drug spend can feel like navigating a treacherous sea in

Litigation Summary and Analysis for Ionis Pharmaceuticals, Inc. v. Arrowhead Pharmaceuticals, Inc. | 2:25-cv-08609 Introduction Ionis Pharmaceuticals, Inc. v. Arrowhead

Introduction: The Generic Paradox – A Growing Market of Shrinking Margins The global generic drug market presents a fundamental paradox

Litigation Summary and Analysis for Arrowhead Pharmaceuticals, Inc. v. Ionis Pharmaceuticals, Inc. | 1:25-cv-01130 Introduction The case Arrowhead Pharmaceuticals, Inc.

A company’s balance sheet tells you its financial health today. Its clinical pipeline tells you what it hopes to achieve

Section 1: The Regulatory Battlefield: A Primer on the Hatch-Waxman Act and Market Exclusivity To the uninitiated, the pharmaceutical industry